Strong beat and raised guidance confirm accelerating organic growth and operating leverage. Upcoming Prosigna LDT and TrueMRD launches could extend the growth trajectory. Expect positive price action at open; watch for sell-side estimate upgrades and potential analyst day catalysts.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $41.19entry
- T+1 · 6mo ago −1.04%α −0.71% · $40.76
- T+5 · 6mo ago −3.96%α −5.09% · $39.56
- T+20 · 6mo ago +18.21%α +15.43% · $48.69
- T+60 · 4mo ago +12.45%α +10.39% · $46.32
Price Chart
How similar events traded
Executive Summary
Veracyte reported Q1 2026 earnings with total revenue of $139.1M (+21% YoY) and GAAP diluted EPS of $0.35, significantly beating Street consensus of $0.23. The company raised full-year 2026 total revenue guidance to $582M-$592M (from $570M-$582M) and adjusted EBITDA margin to >26% (from ~25%), driven by strong Decipher and Afirma testing volume growth.
Key Financial Metrics
Key Facts
- Total revenue $139.1M, +21% YoY
- Testing revenue $135.1M, +26% YoY
- GAAP diluted EPS $0.35 vs Street consensus $0.23 (52% beat)
- Decipher revenue +30% to $86.5M, Afirma revenue +21% to $46.4M
- Raised 2026 total revenue guidance to $582M-$592M (13-14% growth)
- Raised 2026 adjusted EBITDA margin guidance to >26%
- Adjusted EBITDA $42.8M (30.8% margin), +73% YoY
- Operating cash flow $35.2M, FCF $32.3M
- Cash & investments $439.1M at quarter end
Financial Impact
EPS beat of $0.12 (+52%) and guidance raise of $12M at midpoint
Risk Factors
- Execution risk on new product launches (Prosigna LDT, TrueMRD)
- Reimbursement changes for molecular diagnostic tests
- Dependence on Decipher and Afirma growth sustainability
- Biopharmaceutical revenue decline due to Veracyte SAS restructuring
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001384101-26-000029 |
| Document: vcyt-20260505.htm | 0001384101-26-000029 |
| Document: 0001384101-26-000029-index-headers.html | 0001384101-26-000029 |
| Document: 0001384101-26-000029-index.html | 0001384101-26-000029 |
| Document: 0001384101-26-000029.txt | 0001384101-26-000029 |
| 8-K Data (Synthetic) | 0001384101-26-000029 |
Track record
22 reports on VCYT
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.37% at T+20 after the Jun 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $24.63 Now $24.01 −2.52% settles Dec 11
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $50.01 Now $24.01 −51.99% settles Nov 30
- Oct 28, 202619d ago Insider Cluster Neutral 2/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
- Oct 28, 202619d ago Insider Cluster Neutral 3/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
- Sep 22, 20267w ago Insider Cluster Neutral 2/10 Entry $43.82 to $46.22 Now $24.01 −45.21% ▲ +5.48% +4.79% vs SPY
- Sep 14, 20269w ago Press Release Bullish 6/10 Entry $40.14 to $43.11 Now $24.01 −40.18% ▲ +7.40% +4.68% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers